Type 2 diabetes, obesity, and related metabolic diseases all involve abnormalities in glucose homeostasis, pancreatic endocrine function, food intake, and energy balance. GLP-1R can simultaneously regulate insulin secretion, glucagon, gastric emptying, and feeding behavior and has therefore ...
Topic
GLP-1R
Techniques for detecting, quantifying and localizing antigens and antibodies — ELISA, Western blotting, immunohistochemistry and flow cytometry. Below are the protocols, FAQs and technical articles in our knowledge base tagged with this topic.
4 resources · protocols, FAQs & articles
Alzheimer’s disease is jointly driven by Aβ deposition, Tau abnormalities, neuroinflammation, disrupted lipid metabolism, and synaptic injury. Defining the core targets at different pathological stages provides the basis for disease stratification, therapeutic monitoring, and the design of ...
GLP-1R, GIPR, and GCGR jointly regulate pancreatic hormone secretion, hepatic glucose output, feeding behavior, and energy metabolism. Multi-receptor agonists improve the overall metabolic treatment of obesity and type 2 diabetes by balancing glucose-lowering effects, appetite suppression, and ...
Metabolic dysfunction-associated steatohepatitis is jointly driven by hepatic fat accumulation, lipotoxicity, insulin resistance, inflammation, and fibrosis. Targeting lipid metabolism, nuclear receptors, incretin pathways, and FGF signaling has become a major direction in drug development.
Related topics
Techniques often explored alongside immunological experiments.